Amy Carroll1, Pedro T Ramirez1, Shannon N Westin1, Pamela T Soliman1, Mark F Munsell2, Alpa M Nick1, Kathleen M Schmeler1, Ann H Klopp3, Nicole D Fleming4. 1. Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4. Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: nfleming@mdanderson.org.
Abstract
OBJECTIVES: Uterine adenosarcoma is a rare malignancy with little data on optimal management. We aimed to clarify the impact of adjuvant therapy in patients with uterine adenosarcoma and identify risk factors for recurrence and death. METHODS: We performed a retrospective review of patients undergoing primary evaluation and treatment for uterine adenosarcoma at a single institution from July 1982 through December 2011. Univariate and multivariate analyses were used to identify prognostic factors for progression-free survival (PFS) and overall survival (OS). RESULTS: We identified 100 patients with uterine adenosarcoma, and 74 patients met the inclusion criteria. On multivariate analysis, sarcomatous overgrowth (SO) and lymphovascular space invasion (LVSI) were predictors of worse PFS and OS. Median PFS and OS were 29.4 and 55.4 months for patients with SO, compared to 105.9 and 112.4 months for patients without SO (PFS HR 2.58, 95% CI 1.37-4.84, p=0.003; OS HR 2.45, 95% CI 1.26-4.76, p=0.008). Among patients with stage I disease, 17 of 22 patients (77%) with SO and 8 of 37 patients (22%) without SO had a recurrence (p<0.001). Among patients with stage I disease with SO, adjuvant therapy appeared to be associated with longer PFS and OS, but these differences were not statistically significant (PFS, 46.7 vs. 29.4 months, p=0.28; OS, 97.3 vs. 55.4 months, p=0.18). CONCLUSION: In patients with uterine adenosarcoma, the presence of SO or LVSI confers a higher risk of recurrence. We did not identify an optimal treatment strategy for patients with SO, but adjuvant therapy may be associated with prolonged PFS.
OBJECTIVES: Uterine adenosarcoma is a rare malignancy with little data on optimal management. We aimed to clarify the impact of adjuvant therapy in patients with uterine adenosarcoma and identify risk factors for recurrence and death. METHODS: We performed a retrospective review of patients undergoing primary evaluation and treatment for uterine adenosarcoma at a single institution from July 1982 through December 2011. Univariate and multivariate analyses were used to identify prognostic factors for progression-free survival (PFS) and overall survival (OS). RESULTS: We identified 100 patients with uterine adenosarcoma, and 74 patients met the inclusion criteria. On multivariate analysis, sarcomatous overgrowth (SO) and lymphovascular space invasion (LVSI) were predictors of worse PFS and OS. Median PFS and OS were 29.4 and 55.4 months for patients with SO, compared to 105.9 and 112.4 months for patients without SO (PFS HR 2.58, 95% CI 1.37-4.84, p=0.003; OS HR 2.45, 95% CI 1.26-4.76, p=0.008). Among patients with stage I disease, 17 of 22 patients (77%) with SO and 8 of 37 patients (22%) without SO had a recurrence (p<0.001). Among patients with stage I disease with SO, adjuvant therapy appeared to be associated with longer PFS and OS, but these differences were not statistically significant (PFS, 46.7 vs. 29.4 months, p=0.28; OS, 97.3 vs. 55.4 months, p=0.18). CONCLUSION: In patients with uterine adenosarcoma, the presence of SO or LVSI confers a higher risk of recurrence. We did not identify an optimal treatment strategy for patients with SO, but adjuvant therapy may be associated with prolonged PFS.
Authors: C F Verschraegen; A Vasuratna; C Edwards; R Freedman; A P Kudelka; C Tornos; J J Kavanagh Journal: Oncol Rep Date: 1998 Jul-Aug Impact factor: 3.906
Authors: Edward J Tanner; Thomas Toussaint; Mario M Leitao; Martee L Hensley; Robert A Soslow; Ginger J Gardner; Elizabeth L Jewell Journal: Gynecol Oncol Date: 2012-12-30 Impact factor: 5.482
Authors: Benjamin A Nacev; Francisco Sanchez-Vega; Shaleigh A Smith; Cristina R Antonescu; Evan Rosenbaum; Hongyu Shi; Cerise Tang; Nicholas D Socci; Satshil Rana; Rodrigo Gularte-Mérida; Ahmet Zehir; Mrinal M Gounder; Timothy G Bowler; Anisha Luthra; Bhumika Jadeja; Azusa Okada; Jonathan A Strong; Jake Stoller; Jason E Chan; Ping Chi; Sandra P D'Angelo; Mark A Dickson; Ciara M Kelly; Mary Louise Keohan; Sujana Movva; Katherine Thornton; Paul A Meyers; Leonard H Wexler; Emily K Slotkin; Julia L Glade Bender; Neerav N Shukla; Martee L Hensley; John H Healey; Michael P La Quaglia; Kaled M Alektiar; Aimee M Crago; Sam S Yoon; Brian R Untch; Sarah Chiang; Narasimhan P Agaram; Meera R Hameed; Michael F Berger; David B Solit; Nikolaus Schultz; Marc Ladanyi; Samuel Singer; William D Tap Journal: Nat Commun Date: 2022-06-15 Impact factor: 17.694
Authors: Salvatore Piscuoglio; Kathleen A Burke; Charlotte K Y Ng; Anastasios D Papanastasiou; Felipe C Geyer; Gabriel S Macedo; Luciano G Martelotto; Ino de Bruijn; Maria R De Filippo; Anne M Schultheis; Rafael A Ioris; Douglas A Levine; Robert A Soslow; Brian P Rubin; Jorge S Reis-Filho; Britta Weigelt Journal: J Pathol Date: 2015-12-28 Impact factor: 7.996
Authors: Felipe C Geyer; Kathleen A Burke; Salvatore Piscuoglio; Charlotte K Y Ng; Anastasios D Papanastasiou; Caterina Marchiò; Pier Selenica; Marcia Edelweiss; Melissa P Murray; Edi Brogi; Robert A Soslow; Brian P Rubin; Larry Norton; Jorge S Reis-Filho; Britta Weigelt Journal: Mol Oncol Date: 2017-05-16 Impact factor: 6.603